A recent meta-analysis published in the Journal of Psychiatric Research provides evidence that the four most common types of dementia are associated with specific patterns of immune system activity. The findings indicate that these conditions feature distinct inflammatory changes that occur independently of other health problems. These unique immune profiles might eventually help scientists develop targeted treatments for different forms of cognitive decline.
Dementia affects millions of people worldwide and represents a major public health challenge. Emerging evidence suggests that a history of mental health conditions, such as depression or anxiety, might increase a person’s risk of developing dementia later in life. One possible explanation for this connection is the inflammatory-mediated neurodegeneration hypothesis. This concept proposes that mental illness triggers a persistent immune response in the body. Over time, this chronic inflammation might damage the brain and act as a catalyst for cognitive decline.
Inflammation is the immune system’s standard way of protecting the body against injury or infection. It involves various immune cells and the chemical signals they release to coordinate a defense. When this response becomes chronic, these defense mechanisms can sometimes alter how the blood-brain barrier functions. This alteration allows inflammatory molecules to enter the brain and contribute to tissue damage.
Prior reviews have looked at inflammation in Alzheimer’s disease. Most of those reviews did not exclude patients with other known inflammatory conditions, such as arthritis, diabetes, or autoimmune disorders. This made it difficult to tell if the inflammation was genuinely linked to dementia or if it stemmed from other co-occurring health issues. The researchers designed this updated review to isolate the immune changes strictly associated with dementia. They also wanted to see if different types of dementia share the same inflammatory profile or feature unique biological signatures.
To investigate this, the scientists gathered data from 41 previously published studies. The combined sample included 2,256 people diagnosed with dementia and 1,639 healthy control participants matched for age and sex. The studies covered the four most common forms of the condition: Alzheimer’s disease, vascular dementia, dementia with Lewy bodies, and frontotemporal dementia.
A defining feature of this review was its strict inclusion criteria. The researchers only analyzed data from studies that actively screened for and excluded participants with common mental or physical health conditions known to cause inflammation. They looked at 82 different immune markers, including various white blood cells and the signaling proteins they produce, measured in both blood and cerebrospinal fluid.
Thirty-eight studies focused on Alzheimer’s disease, involving 1,953 patients and 1,494 healthy controls. The researchers found that people with Alzheimer’s disease showed moderately higher levels of several specific immune signaling proteins compared to their healthy peers. For example, a protein called Interleukin-17A, which helps regulate immune responses, was consistently elevated. Statistical analysis showed a moderate standardized difference between the groups, meaning the average level of this protein in Alzheimer’s patients was noticeably higher than the healthy average, though individual levels likely varied.
Two other inflammatory mediators, Interleukin-1 alpha and Interleukin-10, also showed moderately higher concentrations in people with Alzheimer’s disease relative to healthy adults. Interestingly, the team did not find differences in some of the most widely studied inflammatory proteins. The variations in the levels of Interleukin-6 and tumor necrosis factor, two major drivers of inflammation, were not statistically significant when comparing the Alzheimer’s and control groups.
The data for the other three types of dementia were much more limited but pointed to distinct immune responses. Vascular dementia was examined in two studies featuring 102 patients and 234 healthy controls. These individuals displayed higher levels of specific signaling proteins known to attract immune cells to sites of tissue damage.
Dementia with Lewy bodies was evaluated across three studies involving 87 patients and 231 controls. This group exhibited elevated levels of a completely different set of inflammatory proteins involved in general immune regulation. Frontotemporal dementia, assessed in two studies with 114 patients and 233 controls, also showed a unique pattern of immune activity. For instance, this group had higher levels of Interleukin-6, a marker that did not differ in the Alzheimer’s group.
When the authors compared the results across all four conditions, they found minimal overlap in the affected immune markers. A few proteins that were elevated in people with Alzheimer’s disease actually appeared at lower levels in people with vascular dementia, dementia with Lewy bodies, and frontotemporal dementia. This divergence indicates that each type of dementia might involve a separate biological pathway rather than a single, universal inflammatory response.
A primary limitation of this research is the cross-sectional nature of the analyzed data. Because the included studies measured immune markers at a single point in time, it is impossible to determine the sequence of events. Inflammation might contribute to the onset of dementia, but the structural brain changes associated with dementia could also be the original trigger that causes the inflammation.
Interpreting these distinct immune profiles as a direct explanation for how mental illness leads to dementia goes beyond the current evidence. The available data cannot confirm whether a history of depression or anxiety actually initiated the inflammatory patterns observed in these patients. The sample sizes for vascular dementia, dementia with Lewy bodies, and frontotemporal dementia were quite small. These specific biological profiles require replication in larger groups before firm conclusions can be drawn.
Future research will need to track individuals over many years, ideally starting in young adulthood or midlife. By repeatedly measuring immune markers over time, scientists can observe whether inflammation precedes cognitive decline. Measuring these markers in cerebrospinal fluid or through brain imaging, rather than just relying on blood samples, will also provide a more accurate picture of inflammation directly within the brain.
The study, “Inflammatory markers associated with dementia: a systematic review and meta-analysis,” was authored by J.K. Kuring, J.L. Mathias, L. Ward, and G. Tachas.